ArticleInternational journal of ophthalmology2022
Clinical efficacy of botulinum toxin type A on acute acquired comitant esotropia.
Article in International journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Comparative efficacy of botulinum toxin and surgical treatment for acute acquired concomitant esotropia: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Clinical efficacy, safety, and success factors of botulinum toxin type A in the treatment of acute acquired comitant esotropia.Japanese journal of ophthalmology · 2026Article
- Botulinum toxin for acute acquired comitant esotropia: clinical outcomes and predictors.BMC ophthalmology · 2025Article
- Long-term efficacy of botulinum toxin for treatment of acquired non-accommodative comitant esotropia.Scientific reports · 2025Article
- Botulinum toxin-A in acute acquired comitant esotropia during COVID pandemic in children and young adolescents.Indian journal of ophthalmology · 2025Article
- Acute-onset Concomitant Esotropia in Children: A Comparison of Clinical Features and Treatment Outcomes.Journal of ophthalmic & vision research · 2025Article
- Advances in the diagnosis and treatment of acute acquired comitant esotropia.International ophthalmology · 2024Review
- Botulinum toxin type A in treating early-stage patients with small-angle acute acquired comitant esotropia.International journal of ophthalmology · 2024Article
- The efficacy of botulinum toxin type A treatment and surgery for acute acquired comitant esotropia.Frontiers in medicine · 2023Article
- Analysis of independent risk factors for acute acquired comitant esotropia.International journal of ophthalmology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the effects of micro-injection of botulinum toxin A (BTXA) on acute acquired comitant esotropia (AACE).
methodsA total of 33 AACE patients who underwent BTXA micro-injection at Renmin Hospital of Wuhan University from September 1
resultsThe average angle of deviation before injection was (+20.24±6.80)
conclusionMicro-injection of BTXA can reduce diplopia and improve binocular vision function of AACE patients. Furthermore, the operation is relatively safe with few complications, making it an ideal treatment modality for AACE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.